Proteomic and metabolomic analysis on chemo-sensitivity and resistance of cancer towards personalized medicine

• Project/Area Number: 23390037
• Research Category: Grant-in-Aid for Scientific Research (B)
• Allocation Type: Single-year Grants
• Section: 一般
• Research Field: Medical pharmacy
• Research Institution: Keio University
• Principal Investigator: TANIGAWARA Yusuke 慶應義塾大学, 医学部, 教授 (30179832)
• Co-Investigator(Kenkyū-buntansha): NISHI Koji 慶應義塾大学, 医学部, 特任講師 (00398249) ; NISHIMUTA Akito 慶應義塾大学, 医学部, 特任助教 (00424135)
• Project Period (FY): 2011-04-01 – 2014-03-31
• Project Status: Completed (Fiscal Year 2013)
• Budget Amount: ¥18,590,000 (Direct Cost: ¥14,300,000、Indirect Cost: ¥4,290,000); Fiscal Year 2013: ¥5,980,000 (Direct Cost: ¥4,600,000、Indirect Cost: ¥1,380,000); Fiscal Year 2012: ¥5,980,000 (Direct Cost: ¥4,600,000、Indirect Cost: ¥1,380,000); Fiscal Year 2011: ¥6,630,000 (Direct Cost: ¥5,100,000、Indirect Cost: ¥1,530,000)
• Keywords: 抗がん剤 / 薬剤反応性 / プロテオーム / メタボローム / オーダーメイド医療 / がん治療 / オキサリプラチン / ゲムシタビン

Research Abstract

Inter-patient variability in the efficacy of cancer pharmacotherapy is one of the most difficult obstacles to improve cancer therapy. The present research investigated cellular mechanisms of pharmacological action of chemotherapeutic agents and resistant mechanisms of cancer against the drug action. The methods we used were the latest proteomic and metabolomic analyses which measured intracellular expression of abundant proteins and metabolites. Based on comprehensive metabolomic fingerprints and protein expression analysis, we have discovered several new proteins and metabolites that are related to the chemo-sensitivity or drug resistance of cancer. These findings are expected to lead to develop a new personalized cancer pharmacotherapy.

Research Products

• [Journal Article] Forced expression of S100A10 reduces sensitivity to oxaliplatin in colorectal cancer cells (2014)
  • Author(s): Suzuki S, Tanigawara Y
  • Journal Title: Proteome Science Volume: 12 Issue: 1 Pages: 26-26
  • DOI: 10.1186/1477-5956-12-26
  • Peer Reviewed / Open Access
• [Journal Article] Clinical practice guidelines for therapeutic drug monitoring of arbekacin: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring (2014)
  • Author(s): Okada K, Kimura T, Mikamo H, Kasahara K, Seki M, Takakura S, Tokimatsu I, Ohmagari N, Takahashi Y, Matsumoto K, Igarashi M, Kobayashi M, Hamada Y, Mochizuki T, Kimura M, Nishi Y, Tanigawara Y, Takesue Y
  • Journal Title: J Infect Chemother Volume: 20(1) Issue: 1 Pages: 1-5
  • DOI: 10.1016/j.jiac.2013.08.008
  • Peer Reviewed
• [Journal Article] Polymorphisms in the UGT1A1 gene predict adverse effects of irinotecan in the treatment of gynecologic cancer in Japanese patients (2013)
  • Author(s): Hirasawa A, Zama T, Akahane T, Nomura H, Kataoka F, Saito K, Okubo K, Tominaga E, Makita K, Susumu N, Kosaki K, Tanigawara Y, Aoki D
  • Journal Title: J Hum Genet Volume: 58(12) Issue: 12 Pages: 794-8
  • DOI: 10.1038/jhg.2013.105
  • Peer Reviewed
• [Journal Article] Pharmacogenetic determinants associated with sunitinib-induced toxicity and ethnic difference in Korean metastatic renal cell carcinoma patients (2013)
  • Author(s): Kim HR, Park HS, Kwon WS, Lee JH, Tanigawara Y, Lim SM, Kim HS, Shin SJ, Ahn JB, Rha SY
  • Journal Title: Cancer Chemother Pharmacol Volume: 72(4) Issue: 4 Pages: 825-35
  • DOI: 10.1007/s00280-013-2258-y
  • Peer Reviewed
• [Journal Article] Population pharmacokinetics and pharmacodynamics of sitafloxacin in patients with community-acquired respiratory tract infections (2013)
  • Author(s): Tanigawara Y, Kaku M, Totsuka K, Tsuge H, Saito A
  • Journal Title: J Infect Chemother Volume: 19(5) Issue: 5 Pages: 858-866
  • DOI: 10.1007/s10156-013-0580-2
  • Peer Reviewed
• [Journal Article] Clinical dose findings of sitafloxacin treatment: pharmacokinetic-pharmacodynamic analysis of two clinical trial results for community-acquired respiratory tract infections (2013)
  • Author(s): Kohno S, Niki Y, Kadota J, Yanagihara K, Kaku M, Watanabe A, Aoki N, Hori S, Fujita J, Tanigawara Y
  • Journal Title: J Infect Chemother Volume: 19(3) Issue: 3 Pages: 486-494
  • DOI: 10.1007/s10156-012-0543-z
  • Peer Reviewed
• [Journal Article] Clinical and bacteriological efficacies of sitafloxacin against community-acquired pneumonia caused by Streptococcus pneumoniae: nested cohort within a multicenter clinical trial (2013)
  • Author(s): Fujita J, Niki Y, Kadota J, Yanagihara K, Kaku M, Watanabe A, Aoki N, Hori S, Tanigawara Y, Cash HL, Kohno S
  • Journal Title: J Infect Chemother Volume: 19(3) Issue: 3 Pages: 472-479
  • DOI: 10.1007/s10156-012-0514-4
  • Peer Reviewed
• [Journal Article] Practice guidelines for therapeutic drug monitoring of voriconazole: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring (2013)
  • Author(s): Hamada Y, Tokimatsu I, Mikamo H, Kimura M, Seki M, Takakura S, Ohmagari N, Takahashi Y, Kasahara K, Matsumoto K, Okada K, Igarashi M, Kobayashi M, Mochizuki T, Nishi Y, Tanigawara Y, Kimura T, Takesue Y
  • Journal Title: J Infect Chemother Volume: 19(3) Issue: 3 Pages: 381-392
  • DOI: 10.1007/s10156-013-0607-8
  • Peer Reviewed
• [Journal Article] Practice guidelines for therapeutic drug monitoring of vancomycin: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring (2013)
  • Author(s): Matsumoto K, Takesue Y, Ohmagari N, Mochizuki T, Mikamo H, Seki M, Takakura S, Tokimatsu I, Takahashi Y, Kasahara K, Okada K, Igarashi M, Kobayashi M, Hamada Y, Kimura M, Nishi Y, Tanigawara Y, Kimura T
  • Journal Title: J Infect Chemother Volume: 19(3) Issue: 3 Pages: 365-380
  • DOI: 10.1007/s10156-013-0599-4
  • Peer Reviewed
• [Journal Article] Dose-adjustment study of tamoxifen based on CYP2D6 genotypes in Japanese breast cancer patients (2012)
  • Author(s): Kiyotani, K., et.al.
  • Journal Title: Breast Cancer Res Treat Volume: 131(1) Issue: 1 Pages: 137-45
  • DOI: 10.1007/s10549-011-1777-7
  • Peer Reviewed
• [Journal Article] Blood-direct InvaderPlus as a new method for genetic testing (2012)
  • Author(s): Hirasawa A, Akahane T, Tanigawara Y, Aoki D
  • Journal Title: Personalized Medicine Volume: 9 Issue: 6 Pages: 657-663
  • DOI: 10.2217/pme.12.71
  • Peer Reviewed
• [Journal Article] A genome-wide association study identifies locus at 10q22 associated with clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients in Japanese (2011)
  • Author(s): K.Kiyotani, T.Mushiroda, T.Tsunoda, T.Morizono, N.Hosono, M.Kubo, Y.Tanigawara, CK.Imamura, DA.Flockhart, F.Aki, K.Hirata, Y.Takatsuka, M.Okazaki, S.Ohsumi, T.Yamakawa, M.Sasa, Y.Nakamura, H.Zembutsu
  • Journal Title: Human Molecular Genetics Volume: (オンライン出版済) Issue: 7 Pages: 1665-1672
  • DOI: 10.1093/hmg/ddr597
  • Peer Reviewed
• [Journal Article] S100A10 protein expression is associated with oxaliplatin sensitivity in human colorectal cancer cells (2011)
  • Author(s): Suzuki S, Yamayoshi Y, Nishimuta A, Tanigawara Y.
  • Journal Title: Proteome Science Volume: 9 Issue: 1 Pages: 76-76
  • DOI: 10.1186/1477-5956-9-76
  • Peer Reviewed
• [Journal Article] Pharmacokinetics of eldecalcitol, a new active D3 derivative (2011)
  • Author(s): M.Abe, N.Tsuji, F.Takahashi, Y.Tanigawara
  • Journal Title: Jpn.Pharmacol.Ther. Volume: 39 Pages: 261-274
  • Peer Reviewed
• [Journal Article] Pharmacokinetics of eldecalcitol in primary osteoporosis patients-Randomaized, double-blind, multicentre, long-term phase III clinical Study (2011)
  • Author(s): K.Miyata, M.Abe, K.Terao, T.Kawanishi, N.Tsuji, M.Shiraki, T.Nakamura, T.Matsumoto, Y.Tanigawara
  • Journal Title: Jpn.Pharmacol.Ther. Volume: 39 Pages: 299-307
  • Peer Reviewed
• [Journal Article] Optimal treatment schedule of meropenem for adult patients with febrile neutropenia based on pharmacokinetic-pharmacodynamic analysis (2011)
  • Author(s): Y.Ohata, Y.Tomita, M.Nakayama, K.Tamura, Y.Tanigawara
  • Journal Title: J.Infect.Chemother. Volume: 17 Issue: 6 Pages: 831-841
  • DOI: 10.1007/s10156-011-0271-9
  • Peer Reviewed
• [Journal Article] Optimal dosage regimen of meropenem for pediatric patients based on pharmacokinetic/pharmacodynamic considerations (2011)
  • Author(s): Y.Ohata, Y.Tomita, M.Nakayama, T.Kozuki, K.Sunakawa, Y.Tanigawara
  • Journal Title: Drug Metab.Pharmacokinet. Volume: 26(5) Pages: 523-531
  • Peer Reviewed
• [Journal Article] Optimal dose finding of garenoxacin based on population pharmacokinetics/pharmacodynamics and Monte Carlo simulation (2011)
  • Author(s): Y.Tanigawara, K.Nozawa, H Tsuda
  • Journal Title: Eur.J.Clin.Pharmacol. Volume: 51 Issue: 1 Pages: 1276-1285
  • DOI: 10.1007/s00228-011-1095-3
  • Peer Reviewed
• [Journal Article] Lowering bile acid pool size with a synthetic farnesoid X receptor (FXR) agonist induces obesity and diabetes through reduced energy expenditure (2011)
  • Author(s): M.Watanabe, Y.Horai, S.M.Houten, K.Morimoto, T.Sugizaki, E.Arita, C.Mataki, H.Sato, Y.Tanigawara
  • Journal Title: J.Biol.Chem. Volume: 286(30) Pages: 26913-20
  • Peer Reviewed
• [Journal Article] A new active vitamin D3 analog, eldecalcitol, prevents the risk of osteoporotic fractures-a randomized active comparator, double-blind study (2011)
  • Author(s): T.Matsumoto, M.Ito, Y.Hayashi, T.Hirota, Y.Tanigawara
  • Journal Title: Bone Volume: 49(4) Pages: 605-612
  • Peer Reviewed
• [Journal Article] A genome-wide association study identifies locus at 10q22 associated with clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients in Japanese (2011)
  • Author(s): K.Kiyotani, T.Mushiroda, T.Tsunoda, T Morizono, N Hosono, M.Kubo, Y.Tanigawara, CK.Imamura, DA Flockhart, F.Aki, K.Hirata, Y.Takatsuka, M.Okazaki, S.Ohsumi, T.Yamakawa, M.Sasa, Y.Nakamura, H.Zembutsu
  • Journal Title: Hum Mol Genet
  • Peer Reviewed
• [Journal Article] Expression changes in arrestin β1 and genetic variation in catechol-O-methyltransferase are biomarkers for the response to morphine treatment in cancer patients (2011)
  • Author(s): H.Matsuoka, T.Arao, C.Makimura, M.Takeda, H.Kiyota, J.Tsurutani, Y.Fujita, K.Matsumoto, H.Kimura, M.Otsuka, A.Koyama, CK.Imamura, Y.Tanigawara, T.Yamanaka, K.Tanaka, K.Nishio, K.Nakagawa
  • Journal Title: Oncology Reports Volume: 27(5) Pages: 1393-9
  • DOI: 10.3892/or.2012.1660
  • Peer Reviewed
• [Journal Article] Levofloxacin注射剤の母集団薬物動態/薬力学解析 (2011)
  • Author(s): 谷川原祐介, 清水貴子, 戸塚恭一
  • Journal Title: 日本化学療法学会雑誌 Volume: 59(S-1) Pages: 55-63
  • NAID: 10028244755
  • Peer Reviewed
• [Presentation] Pharmacogenomics-based personalized dosing of tamoxifen : Solution for controversy (2013)
  • Author(s): Tanigawara Y
  • Organizer: 第72回日本癌学会学術総会
  • Place of Presentation: 横浜
  • Year and Date: 2013-10-04
  • Invited
• [Presentation] ヒト大腸がん細胞における5-FU 耐性のメタボローム解析 (2013)
  • Author(s): 藤原裕, 西牟田章戸, 川島知憲, 谷川原祐介
  • Organizer: 第72回日本癌学会学術総会
  • Place of Presentation: 横浜
  • Year and Date: 2013-10-03
• [Presentation] ヒト膵臓細胞におけるゲムシタビン耐性のメタボローム解析 (2013)
  • Author(s): 森本洋輔, 西 弘二, 川島知憲, 谷川原祐介
  • Organizer: 第72回日本癌学会学術総会
  • Place of Presentation: 横浜
  • Year and Date: 2013-10-03
• [Presentation] Cancer biomarkers in diagnostics and pharmacotherapy (2013)
  • Author(s): Tanigawara Y
  • Organizer: FIP (International Pharmaceutical Federation)
  • Place of Presentation: Dublin, Ireland
  • Year and Date: 2013-09-03
  • Invited
• [Presentation] がん薬物療法の個別化に向けたPK/PD と統合オミックス研究 (2013)
  • Author(s): 谷川原祐介
  • Organizer: 第50回薬剤学懇談会研究討論会
  • Place of Presentation: 札幌
  • Year and Date: 2013-06-26
• [Presentation] TDM のサイエンスとプラクティス (2013)
  • Author(s): 谷川原祐介
  • Organizer: 第30回日本TDM 学会・学術大会
  • Place of Presentation: 熊本
  • Year and Date: 2013-05-26
• [Presentation] メタボローム解析によるヒト大腸癌細胞の5-FU+オキサリプラチンに対する応答機構の解明 (2012)
  • Author(s): 津崎盾哉, 西牟田章戸, 谷川原祐介
  • Organizer: 第10回日本臨床腫瘍学会学術集会
  • Place of Presentation: 大阪
  • Year and Date: 2012-07-27
• [Presentation] Pharmaco-metabolomics for anticancer drugs (2012)
  • Author(s): Tanigawara Y
  • Organizer: 第10回日本臨床腫瘍学会学術集会
  • Place of Presentation: 大阪
  • Year and Date: 2012-07-26
• [Presentation] Pharmaco-metabolomics of anticancer drugs (2012)
  • Author(s): Tanigawara Y
  • Organizer: 10th International Conference of the Asian Clinical Oncology Society
  • Place of Presentation: Seoul, Korea
  • Year and Date: 2012-06-14
• [Presentation] シンポジウム「がん領域における薬剤師の能力向上」 (2012)
  • Author(s): 谷川原祐介
  • Organizer: 第33回日本病院薬剤師会近畿学術大会
  • Place of Presentation: ATCホール(大阪府)(招待講演)
  • Year and Date: 2012-01-21
• [Presentation] Pharmaco-metabolomics of anticancer drugs (2012)
  • Author(s): Y. Tanigawara
  • Organizer: 10th International Conference of the Asian Clinical Oncology Society
  • Place of Presentation: Seoul (Korea)
  • Invited
• [Presentation] 我が国におけるバイオマーカー研究の現状：Pharmaco-metabolomics for anticancer drugs (2012)
  • Author(s): 谷川原祐介
  • Organizer: 第10回日本臨床腫瘍学会学術集会
  • Place of Presentation: 大阪
  • Invited
• [Presentation] シンポジウム「母集団薬物動態解析を用いた薬物遺伝学」 (2011)
  • Author(s): 谷川原祐介
  • Organizer: 第32回日本臨床薬理学会年会
  • Place of Presentation: アクトシティ浜松(静岡県)(招待講演)
  • Year and Date: 2011-12-01
• [Presentation] Pharmacogenomics (2011)
  • Author(s): Tanigawara Y
  • Organizer: 第49回日本癌治療学会学術集会
  • Place of Presentation: 名古屋
  • Year and Date: 2011-11-28
  • Invited
• [Presentation] Post-genome proteomic and metabolomic analyses for pharmacological responses to anticancer agents (2011)
  • Author(s): Tanigawara Y
  • Organizer: 第49回日本癌治療学会学術集会
  • Place of Presentation: 名古屋
  • Year and Date: 2011-11-27
  • Invited
• [Presentation] 基調講演「クリニカル・クエスチョンから臨床研究へ」 (2011)
  • Author(s): 谷川原祐介
  • Organizer: 日本病院薬剤師会東海ブロック・日本薬学会東海支部合同学術大会2011
  • Place of Presentation: ウインク愛知(愛知県)(招待講演)
  • Year and Date: 2011-11-23
• [Presentation] シンポジウム「Current status of PGx applications in medical practice」 (2011)
  • Author(s): 谷川原祐介
  • Organizer: 日本薬物動態学会第26回年会
  • Place of Presentation: 広島国際会議場(広島県)(招待講演)
  • Year and Date: 2011-11-18
• [Presentation] Cancer metabolomics by MS technology (2011)
  • Author(s): Tanigawara Y
  • Organizer: 12th International Congress of Therapeutic Drug Monitoring & Clinical Toxicology (Plenary Lecture)
  • Place of Presentation: Stuttgart, Germany
  • Year and Date: 2011-11-06
• [Presentation] Presidential Symposium 3 "Mega-clinical trial in Pan-Asia-Towards the golden standard therapy in Asia-", SPS3-3 "Pharmacogenomics" (2011)
  • Author(s): Yusuke Tanigawara
  • Organizer: 49th Annual Meeting of Japan Society of Clinical Oncology
  • Place of Presentation: Nagoya Congress Center, Aichi, Japan(招待講演)
  • Year and Date: 2011-10-28
• [Presentation] International Session "Pharmacogenomics", IS-6 "Post-genome proteomicand metabolomic analyses for pharmacological responses to anticancer agents" (2011)
  • Author(s): Yusuke Tanigawara
  • Organizer: 49th Annual Meeting of Japan Society of Clinical Oncology
  • Place of Presentation: Nagoya Congress Center, Aichi, Japan(招待講演)
  • Year and Date: 2011-10-27
• [Presentation] Plenary Lecture "Cancer metabolomics by MS technology" (2011)
  • Author(s): Yusuke Tanigawara
  • Organizer: 12th International Congress of Therapeutic Drug Monitoring & Clinical Toxicology
  • Place of Presentation: Stuttgart, Germany(招待講演)
  • Year and Date: 2011-10-06
• [Presentation] シンポジウム「がん専門薬剤師による薬学的介入・薬剤管理指導の実際」 (2011)
  • Author(s): 谷川原祐介
  • Organizer: 第21回日本医療薬学会年会
  • Place of Presentation: 神戸国際展示場(兵庫県)(招待講演)
  • Year and Date: 2011-10-01
• [Presentation] メタボローム解析による大腸癌細胞のオキサリプラチン感受性因子の探索 (2011)
  • Author(s): 大谷勇紀, 西牟田章戸, 谷川原祐介
  • Organizer: 第9回日本臨床腫瘍学会学術集会
  • Place of Presentation: 横浜
  • Year and Date: 2011-07-21
• [Presentation] シンポジウム「がん薬物療法の薬学的ケア」 (2011)
  • Author(s): 谷川原祐介
  • Organizer: 医療薬学フォーラム2011
  • Place of Presentation: 旭川市民文化会館(北海道)(招待講演)
  • Year and Date: 2011-07-09
• [Presentation] メロペネム高用量投与の可能性1.メロペネム3g投与におけるPK/PD (2011)
  • Author(s): 谷川原祐介
  • Organizer: 第59回日本化学療法学会総会
  • Place of Presentation: 札幌コンベンションセンター(北海道)(招待講演)
  • Year and Date: 2011-06-25
• [Presentation] Cancer biomarkers in diagnostics and pharamacotherapy
  • Author(s): Yusuke Tanigawara
  • Organizer: FIP (International Pharmaceutical Federation)
  • Place of Presentation: Dublin, Ireland
  • Invited
• [Presentation] Pharmacogenomics-based personalized dosing of tamoxifen: Solution for controversy
  • Author(s): Yusuke Tanigawara
  • Organizer: 第72回日本癌学会学術総会
  • Place of Presentation: 横浜
  • Invited
• [Presentation] 患者に優しい化学療法
  • Author(s): 谷川原祐介
  • Organizer: 日本薬剤学会第28年会
  • Place of Presentation: 愛知
  • Invited
• [Presentation] 特別講演「TDMのサイエンスとプラクティス」
  • Author(s): 谷川原祐介
  • Organizer: 第30回日本TDM学会・学術大会
  • Place of Presentation: 熊本
  • Invited
• [Presentation] がん薬物療法の個別化に向けたPK/PDと統合オミックス研究
  • Author(s): 谷川原祐介
  • Organizer: 第50回薬剤学懇談会研究討論会
  • Place of Presentation: 札幌
  • Invited
• [Presentation] 抗がん剤の薬理学
  • Author(s): 谷川原祐介
  • Organizer: 第51回日本癌治療学会学術集会
  • Place of Presentation: 京都
  • Invited
• [Presentation] 医療からみた創薬・治療薬開発研究のイノベーション：クリニカル・クエスチョンから臨床研究へ：タモキシフェンの薬理遺伝学的研究
  • Author(s): 谷川原祐介
  • Organizer: 日本薬学会第134年会
  • Place of Presentation: 熊本
  • Invited
• [Presentation] ヒト大腸がん細胞における5-FU耐性のメタボローム解析
  • Author(s): 藤原 裕、西牟田章戸、川島知憲、谷川原祐介
  • Organizer: 第72回日本癌学会学術総会
  • Place of Presentation: 横浜
• [Presentation] ヒト膵癌細胞におけるゲムシタビン耐性のメタボローム解析
  • Author(s): 森本洋輔、西 弘二、川島知憲、谷川原祐介
  • Organizer: 第72回日本癌学会学術総会
  • Place of Presentation: 横浜
• [Book] 薬物動態・薬力学から見たがん個別化治療の現状と展望 (2014)
  • Author(s): 谷川原祐介
  • Publisher: 日本臨床社
• [Book] 薬物動態・薬力学から見たがん個別化治療の現状と展望，日本臨牀 72巻 増刊号2 (2014)
  • Author(s): 谷川原祐介
  • Total Pages: 7
  • Publisher: 日本臨牀社
• [Book] Population Pharmacokinetics解析法，薬剤学実験法必携マニュアルII (2014)
  • Author(s): 谷川原祐介、笠井英史
  • Total Pages: 17
  • Publisher: 南江堂
• [Book] ポピュレーション・ファーマコキネティクス，医療薬学 第６版 (2014)
  • Author(s): 谷川原祐介
  • Total Pages: 5
  • Publisher: 廣川書店
• [Book] 薬物治療モニタリング（TDM），今日の治療指針2013年版 (2013)
  • Author(s): 谷川原祐介
  • Total Pages: 13
  • Publisher: 医学書院
• [Book] 化学療法の領域27(1)(巻頭言:個別化投薬-過去,現在,未来-) (2011)
  • Author(s): 谷川原祐介
  • Total Pages: 15
  • Publisher: 医療ジャーナル社
• [Book] 薬事日報,第10927号(がん専門薬剤師認定制度の現状) (2011)
  • Author(s): 谷川原祐介
  • Total Pages: 12
  • Publisher: 薬事日報社
• [Book] 薬物治療モニタリング(TDM) (2011)
  • Author(s): 谷川原祐介
  • Total Pages: 1575
  • Publisher: 医学書院
• [Book] 安全医学7(1) (2011)
  • Author(s): 谷川原祐介
  • Total Pages: 47
  • Publisher: 日本予防医学リスクマネージメント学会
• [Patent(Industrial Property Rights)] 抗がん剤感受性判定マーカー (2014)
  • Inventor(s): 谷川原祐介, 渡辺光博, 有田恵理, 西牟田章戸, 山吉康子, 松崎 健, 杉本伸二
  • Industrial Property Rights Holder: 学校法人慶應義塾, 株式会社ヤクルト本社
  • Industrial Property Rights Type: 特許
  • Acquisition Date: 2014-03-12
  • Overseas
• [Patent(Industrial Property Rights)] 抗がん剤感受性判定マーカー (2014)
  • Inventor(s): 谷川原祐介, 渡辺光博, 有田恵理, 西牟田章戸, 山吉康子, 松崎 健, 杉本伸二
  • Industrial Property Rights Holder: 学校法人慶應義塾, 株式会社ヤクルト本社
  • Industrial Property Rights Type: 特許
  • Acquisition Date: 2014-01-24
• [Patent(Industrial Property Rights)] 抗がん剤感受性の判定方法 (2014)
  • Inventor(s): 谷川原祐介, 鈴木小夜, 杉本伸二
  • Industrial Property Rights Holder: 学校法人慶應義塾, 株式会社ヤクルト本社
  • Industrial Property Rights Type: 特許
  • Acquisition Date: 2014-01-24
• [Patent(Industrial Property Rights)] 抗がん剤感受性の判定マーカー (2012)
  • Inventor(s): 谷川原祐介, 西牟田章戸, 大谷勇紀, 松尾光寿
  • Industrial Property Rights Holder: 学校法人慶應義塾, 株式会社ヤクルト本社
  • Industrial Property Rights Type: 特許
  • Filing Date: 2012-03-24
  • Overseas
• [Patent(Industrial Property Rights)] 併用抗がん剤の感受性判定マーカー (2012)
  • Inventor(s): 谷川原祐介, 西牟田章戸, 津崎盾哉, 高橋寛行
  • Industrial Property Rights Holder: 学校法人慶應義塾, 株式会社ヤクルト本社
  • Industrial Property Rights Type: 特許
  • Industrial Property Number: 2012-037448
  • Filing Date: 2012-02-23
• [Patent(Industrial Property Rights)] 抗がん剤の感受性の判定方法 (2012)
  • Inventor(s): 谷川原祐介, 西牟田章戸, 鈴木小夜, 鈴木哲也, 生駒祐介, 杉本伸二
  • Industrial Property Rights Holder: 学校法人慶應義塾, 株式会社ヤクルト本社
  • Industrial Property Rights Type: 特許
  • Acquisition Date: 2012-03-24
  • Overseas
• [Patent(Industrial Property Rights)] 抗がん剤の感受性の判定方法 (2012)
  • Inventor(s): 谷川原祐介、西牟田章戸、鈴木小夜、鈴木哲也、生駒祐介、杉本伸二
  • Industrial Property Rights Holder: 谷川原祐介、西牟田章戸、鈴木小夜、鈴木哲也、生駒祐介、杉本伸二
  • Industrial Property Rights Type: 特許
  • Filing Date: 2012-04-30
  • Acquisition Date: 2014-03-24
  • Overseas
• [Patent(Industrial Property Rights)] 抗がん剤感受性の判定マーカー (2012)
  • Inventor(s): 谷川原祐介, 西牟田章戸, 大谷勇紀, 松尾光寿
  • Industrial Property Rights Holder: 学校法人慶應義塾株式会社ヤクルト本社
  • Filing Date: 2012-03-24
  • Overseas
• [Patent(Industrial Property Rights)] 抗がん剤感受性の判定マーカー (2011)
  • Inventor(s): 谷川原祐介, 西牟田章戸, 大谷勇紀, 松尾光寿
  • Industrial Property Rights Holder: 学校法人慶應義塾株式会社ヤクルト本社
  • Industrial Property Number: 2011-065993
  • Filing Date: 2011-03-24